ProQR clinical trial: LCA10

ProQR are conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat LCA 10. Sepofarsen is designed to repair the CEP290 RNA defect and produce a normal functioning CEP290 protein, which will result in improved vision in participants. This study is ongoing in a number of clinical centres in North America and Europe, involving 30 patients over a 25 month period.


More information about the Illuminate trial can be found on the ProQR and Illuminate websites.


To keep up to date with our news and activities,
please leave your details below

Please indicate your consent for Retina International to contact you via the email address listed for the purposes of general alerts and newsletters.

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.